Fluidigm Corporation Stock Company Profile

Description

Fluidigm Corporation creates, manufactures, and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics. It offers C1 single-cell auto prep system that isolates and processes individual cells for genomic analysis; access array system, which enables automated polymerase chain reaction (PCR)-based target enrichment, barcoding, and tagging of targeted sequencing libraries and facilitates parallel amplification; Juno system and integrated fluidic circuits (IFCs), which automate the preparation of samples for genomic analysis; and Callisto system and IFC that enable automated cell culture and combinatorial dosing on a single device. The company also provides Polaris system and IFCs; Biomark HD system, a PCR analytical instrument for gene expression analysis, single-cell targeted gene expression analysis, microRNA analysis, single nucleotide polymorphism (SNP) genotyping, and digital PCR; and Helios/CyTOF 2 system, a mass cytometry instrument that performs single-cell protein analysis. In addition, it offers C1, access array, dynamic array, digital array, flex six, and high-throughput C1 mRNA sequencing IFCs; and Delta Gene and SNP type assays, access array target-specific primers, and targeted sequencing prep primers, as well as Maxpar reagents. Further, the company provides imaging mass cytometer instrument and reagents, laser ablation module, and other Maxpar reagent products. It serves academic institutions; clinical laboratories; and pharmaceutical, biotechnology, and agricultural biotechnology companies through its direct sales force and support organizations, distributors, or sales agents. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.